Baseline and salt-stimulated paraoxonase and arylesterase activities in patients with chronic liver disease: Relation to disease severity

Internal Medicine Journal

Volumn 39, Issue 4, 2009, Pages 243-248

  Keskin, M ^a   Dolar, E ^a   Dirican, M ^b   Kiyici, M ^a   Yilmaz, Y ^c   Gurel, S ^a   Nak, S G ^a   Erdinc, S ^b   Gulten, M ^a  

^a Departments of Gastroenterology

^b Departments of Biochemistry

^c ULUDAG UNIVERSITY   (Turkey)

Author keywords

Arylesterase; Chronic liver disease; Cirrhosis; Liver function tests; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLESTERASE;

ADULT; ARTICLE; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; HUMAN; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; ALANINE TRANSAMINASE; APOLIPOPROTEIN A-I; ARYLDIALKYLPHOSPHATASE; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; BIOLOGICAL MARKERS; CARBOXYLIC ESTER HYDROLASES; CHOLESTEROL; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PHENOTYPE; ROC CURVE; SEVERITY OF ILLNESS INDEX; SODIUM CHLORIDE; STIMULATION, CHEMICAL; TRIGLYCERIDES;

EID: 65349098761     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2009.01793.x     Document Type: Article

References (21)

1. La Du BN, Aviram M, Billecke S, Navab M, Primo-Parmo S, Sorenson RC et al. On the physiological role(s) of the paraoxonases. Chem Biol Interact 1999 119-120 : 379 88.
2. Aslan M, Kosecik M, Horoz M, Selek S, Celik H, Erel O. Assessment of paraoxonase and arylesterase activities in patients with iron deficiency anemia. Atherosclerosis 2007 191 : 397 402.
3. Hu Y, Tian H, Liu R. Gln-Arg192 polymorphism of paraoxonase 1 is associated with carotid intima-media thickness in patients of type 2 diabetes mellitus of Chinese. Diabetes Res Clin Pract 2003 61 : 21 7.
4. Kakafika AI, Xenofontos S, Tsimihodimos V, Tambaki AP, Lourida ES, Kalaitzidis R et al. The PON1 M55L gene polymorphism is associated with reduced HDL-associated PAF-AH activity. J Lipid Res 2003 44 : 1919 26.
5. Sepahvand F, Shafiei M, Ghaffari SM, Rahimi-Moghaddam P, Mahmoudian M. Paraoxonase phenotype distribution in a healthy Iranian population. Basic Clin Pharmacol Toxicol 2007 101 : 104 7.
6. Sentí M, Tomás M, Fitó M, Weinbrenner T, Covas MI, Sala J et al. Antioxidant paraoxonase 1 activity in the metabolic syndrome. J Clin Endocrinol Metab 2003 88 : 5422 6.
7. Mackness MI, Durrington PN, Mackness B. The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention. Am J Cardiovasc Drugs 2004 4 : 211 17.
8. Ferré N, Camps J, Prats E, Vilella E, Paul A, Figuera L et al. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002 48 : 261 8.
9. Kilic SS, Aydin S, Kilic N, Erman F, Aydin S, Celik I. Serum arylesterase and paraoxonase activity in patients with chronic hepatitis. World J Gastroenterol 2005 11 : 7351 4.
10. Kutlu R, Karaman I, Akbulut A, Baysal T, Sigirci A, Alkan A et al. Quantitative Doppler evaluation of the splenoportal venous system in various stages of cirrhosis: differences between right and left portal veins. J Clin Ultrasound 2002 30 : 537 43.
11. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983 35 : 1126 38.
12. Haagen L, Brock A. A new automated method for phenotyping arylesterase (EC 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 1992 30 : 391 5.
13. Yamamoto Y, Yamashita S, Fujisawa A, Kokura S, Yoshikawa T. Oxidative stress in patients with hepatitis, cirrhosis, and hepatoma evaluated by plasma antioxidants. Biochem Biophys Res Commun 1998 247 : 166 70.
14. Ferré N, Camps J, Cabré M, Paul A, Joven J. Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Metabolism 2001 50 : 997 1000.
15. Blatter Garin MC, Moren X, James RW. Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I. J Lipid Res 2006 47 : 515 20.
16. Juretić D, Tadijanović M, Rekić B, Simeon-Rudolf V, Reiner E, Baricić M. Serum paraoxonase activities in hemodialyzed uremic patients: cohort study. Croat Med J 2001 42 : 146 50.
17. Schiavon R, De Fanti E, Giavarina D, Biasioli S, Cavalcanti G, Guidi G. Serum paraoxonase activity is decreased in uremic patients. Clin Chim Acta 1996 247 : 71 80.
18. Campbell MS, Reddy KR. Review article: the evolving role of liver biopsy. Aliment Pharmacol Ther 2004 20 : 249 59.
19. Seres I, Paragh G, Deschene E, Fulop T Jr., Khalil A. Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp Gerontol 2004 39 : 59 66.
20. Marsillach J, Ferré N, Vila MC, Lligoña A, Mackness B, Mackness M et al. Serum paraoxonase-1 in chronic alcoholics: relationship with liver disease. Clin Biochem 2007 40 : 645 50.
21. Liao F, Zhu XY, Wang YM, Zhao YS, Zhu LP, Zuo YP. Correlation of serum arylesterase activity on phenylacetate estimated by the integrated method to common classical biochemical indexes of liver damage. J Zhejiang Univ Sci B 2007 8 : 237 41.